We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

183 hedge funds and large institutions have $751M invested in Eagle Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 73 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $1.99M

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 180 → 183 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1% less capital invested

Capital invested by funds: $756M → $751M (-$4.85M)

22% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 73

Holders
183
Holders Change
+3
Holders Change %
+1.67%
% of All Funds
4.01%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
57
Reduced
73
Closed
14
Calls
$4.24M
Puts
$1.99M
Net Calls
+$2.24M
Net Calls Change
+$4.87M

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$12.2M
2
LSV Asset Management
LSV Asset Management
Illinois
+$3.22M
3
MCM
Matarin Capital Management
New York
+$2.36M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.04M
5
ZIM
Zacks Investment Management
Illinois
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
-$11.6M
2
State Street
State Street
Massachusetts
-$6.46M
3
DZ Bank
DZ Bank
Germany
-$5.55M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$3.45M
5
Invesco
Invesco
Georgia
-$2.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
EGM
76
Engineers Gate Manager
New York
$1.14M +$1.14M +20,224 New
OA
77
Oak Associates
Ohio
$1.14M – – –
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$1.11M +$24.2K +431 +2%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$1.08M +$302K +5,373 +39%
Citigroup
80
Citigroup
New York
$1.07M +$774K +13,762 +270%
SB
81
Suntrust Banks
Georgia
$1.04M +$7.48K +133 +0.7%
Fisher Asset Management
82
Fisher Asset Management
Washington
$1.01M – – –
Jacobs Levy Equity Management
83
Jacobs Levy Equity Management
New Jersey
$952K +$33.2K +590 +4%
Deutsche Bank
84
Deutsche Bank
Germany
$945K +$84.9K +1,510 +10%
T. Rowe Price Associates
85
T. Rowe Price Associates
Maryland
$864K +$14.1K +250 +2%
MF
86
Magnetar Financial
Illinois
$858K -$19.1K -339 -2%
KBC Group
87
KBC Group
Belgium
$855K +$680K +12,100 +400%
HTC
88
Hershey Trust Company
Pennsylvania
$854K – – –
Ohio Public Employees Retirement System (OPERS)
89
Ohio Public Employees Retirement System (OPERS)
Ohio
$816K +$382K +6,801 +89%
State of Wisconsin Investment Board
90
State of Wisconsin Investment Board
Wisconsin
$815K – – –
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
$808K – – –
State Board of Administration of Florida Retirement System
92
State Board of Administration of Florida Retirement System
Florida
$767K +$326K +5,796 +75%
SEI Investments
93
SEI Investments
Pennsylvania
$760K +$125K +2,230 +20%
VOYA Investment Management
94
VOYA Investment Management
Georgia
$752K +$252K +4,477 +51%
Capital Fund Management (CFM)
95
Capital Fund Management (CFM)
France
$681K +$677K +12,035 New
ASRS
96
Arizona State Retirement System
Arizona
$672K -$231K -4,105 -26%
GCP
97
GSA Capital Partners
United Kingdom
$670K -$403K -7,164 -38%
SO
98
STRS Ohio
Ohio
$656K -$45K -800 -6%
Envestnet Asset Management
99
Envestnet Asset Management
Illinois
$629K +$73.1K +1,300 +13%
HSBC Holdings
100
HSBC Holdings
United Kingdom
$590K +$586K +10,421 New
2 3
4
5 6

EGRX Hedge Fund Activity: Q3 2019 in Review

183 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2019, worth a combined $751M — down 0.64% from $756M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EGRX positions and 14 closed out — a net gain of 3 holders — while 57 added to existing stakes and 73 trimmed.

The largest buyer was Credit Suisse, adding an estimated $12.2M. The largest seller was Park West Asset Management, cutting an estimated $11.6M.

  • 183 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2019, up from 180 in Q2 2019.
  • Funds reported $751M of Eagle Pharmaceuticals, Inc. stock for Q3 2019, down 0.64% quarter-over-quarter.
  • 17 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2019 and 14 closed out, a net change of +3 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2019 was Credit Suisse, an estimated $12.2M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q3 2019 was Park West Asset Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2019.